Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SAS the first Nordic airline to launch high speed WiFi

Passengers on SAS short and medium haul routes will now have access to a stable, fast and strong WiFi signal, enabling them to stream and work inflight problem-free.Today, SAS is launching new high speed WiFi on its short and medium haul routes between Scandinavia and Europe. The new WiFi system from SAS is the best product on the market. It is more stable, stronger and faster than many other solutions found in the industry today. This means that passengers can now stream their favorite movies, use social media, send images from their seat or answer their emails. “We have made a big

Bona introduces a new, professional care and maintenance program for wood and resilient floors

Based on a century of experience in wood floor treatment, Bona’s revolutionary new floor care program for both wood and resilient sets a new paradigm in floor care. This new program offers much more than just great detergents; it provides floor care professionals with expert guidance, sustainable products and solutions required to protect and maintain floors, ensuring they remain beautiful for longer. Developed for professional cleaners, caretakers, building service contractors and traditional wood floor contractors, this innovative program enables the floor owner to more

Photocure ASA: Presentation of the first quarter 2018 results

Photocure will present its first quarter 2018 report on Wednesday 23 May 2018 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will be Kjetil Hestdal, President & CEO and Erik Dahl, CFO. The presentation will be held in Norwegian.The presentation will be publicly available at www.photocure.com. It will be possible to follow the presentation through http://webtv.hegnar.no/presentation.php?webcastId=83489783. A light snack will be served from 08:00 (CET). The presentation is scheduled to conclude at 09:15 (CET).

Episurf Medical will exhibit at the 19th EFORT Congress, held in Barcelona, Spain, on May 30 – June 1

Episurf Medical (NASDAQ: EPIS B) will exhibit at the 19thEFORT Congress, Europe’s largest orthopaedic conference, held in Barcelona, Spain (FIRA Gran Via), on May 30 – June 1. For full program, see https://www.efort.org/barcelona2018. For an overview of the industry conferences attended by Episurf Medical, see link. (www.episurf.com/healthcare-professionals/conferences).   For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock, Inc ownership in Valmet exceeds 5 percent

Valmet Oyj's stock exchange release on May 16, 2018 at 1:30 p.m. EET Valmet Oyj has on May 15, 2018 received a notification referred to in Securities Market Act from BlackRock, Inc, stating that the company's ownership and share of votes in Valmet Oyj has exceeded the threshold of 5 percent.                                                                                                                         As a result of transactions on May 14, 2018, the holding of BlackRock, Inc increased to 7,499,877 shares, representing an ownership of 5.00 percent of Valmet Oyj's total number

Xspray Pharma Chariman divests 4,000 shares to cover Danish capital gains tax on unrealised gains on Xspray Pharma shares

Xspray Pharma’s Chairman, Michael Wolff Jensen’s private, fully owned holding company MWJ Partners ApS has sold 4,000 shares in Xspray Pharma. The proceeds cover incurred Danish capital gains tax, which is charged on unrealized capital gains on MWJ Partners’ holding of shares in Xspray Pharma. After the transaction, Michael Wolff Jensen holds 31,864 shares and 25,000 warrants via his company.”As the tax is charged on unrealized capital gains solely on the holding of Xspray Pharma shares in my private holding company, I have decided to cover the tax by divesting the same kind of assets as

Berghs School of Communication in Stockholm invites the world to a digital exhibition

The exhibition is conceptualized, produced and curated by the Student Agency, consisting of ten of this year’s graduates. The Student Agency was given a brief by Berghs in early February, stating that the exhibition had to be an international event and that the priority was to highlight the students. The result is a concept where factors of change and influence are being explored, in which the graduating student are being incorporated throughout. In order to meet the wish for a digital experience of the exhibition, everything will be photographed using a 360 camera. The 360 experience will

EQT to sell global medtech company HTL-Strefa

·  EQT V to sell global medtech company HTL to Investindustrial. Following the acquisition, HTL will be combined with Artsana’s healthcare business PIC ·  During EQT’s ownership, HTL has transformed into an innovative medtech company with a global leadership position in medical sharp devices ·  The transformation has enabled strong organic growth and improved profitability through strong customer focus and relentless drive to commercialize innovation  ·  New management has led HTL into the next level of growth based on a newly developed and already proven growth strategy that

Vattenfall commences construction of one of Sweden’s largest wind farms

Construction of the Blakliden/Fäbodberget wind farm in the Åsele and Lycksele municipalities is now starting. The wind farm cluster will have a total of 84 turbines and, when operational in 2021/2022, it will be one of Sweden's largest onshore wind farms and Vattenfall´s largest. Around 60 percent of the production will be sold in a 20-year agreement. Furthermore, Vattenfall is bringing two partners onboard as shareholders.Vattenfall has signed a turbine contract with Vestas and, subject to project financing being in place, a 20-year power purchase agreement with Norsk Hydro will be closed.

Vestas partners with Swedish utility, Vattenfall, and Danish pension fund, PKA, for 353 MW wind energy project in Sweden

News release from Vestas Northern & Central EuropeHamburg, 16 May 2018 With wind energy becoming the lowest cost of energy solution in many markets, the global wind energy market is expanding and creating new opportunities that involve new customer segments, partnership constellations, technology solutions and financing structures. As the global leader in wind energy, Vestas continues to be highly involved in this evolution and is together with key partners developing solutions that address a wind park’s full value chain and hereby maximise return on investment and profitability.

Cantargia’s immuno-oncology project CAN04 shows promise in additional cancer forms

Cantargia AB today announces that the company has generated novel data showing high levels of interleukin-1 receptor accessory protein (IL1RAP) in tumors from patients with liver cancer, esophageal cancer as well as head and neck cancer. In addition, Cantargia’s lead candidate CAN04, an IL1RAP binding antibody in clinical trials, showed potent antitumor activity in in vitro models of these cancer forms.Cantargia has previously presented data showing that IL1RAP is overexpressed on tumor cells from patients with e.g. non-small cell lung cancer, pancreatic cancer, breast cancer and various

Make cleaning cheaper and safer by using the right amount of detergents

Using the proper amount of cleaning product is one way of ensuring the safe use of cleaning products developed for professional use. In addition to improving work safety, using the correct amount of product also has many other benefits. Kiilto product development manager and product safety specialist Tomi Peltonen recommends using just the right amounts of cleaning agents, as this saves time and money, reduces the burden on the environment and, above all, ensures the best cleaning results. Read what Tomi has to say on the subject.Follow the instructions! By using the right amount of

Selvaag Bolig ASA: Invitation to presentation of first quarter 2018 results

Selvaag Bolig ASA will publish its first quarter 2018 results on Wednesday 23 May at 07:00 am CET.The quarterly report and the presentation materials will be available on the company's website, www.selvaagboligasa.no/english and www.newsweb.no, as well as news wires.CEO Baard Schumann and CFO Sverre Molvik will present the company's results at 08:30 am CET at Høyres Hus, Stortingsgaten 20 in Oslo. A light breakfast will be served from 08:00.The presentation will be held in Norwegian and transferred via live webcast. The link to the webcast can be found on the company's website. It

30.6 million people displaced inside their country in 2017

Conflict and disasters displaced 30.6 million people within their own countries last year, according to a new report from the Internal Displacement Monitoring Centre (IDMC) and the Norwegian Refugee Council (NRC).“This is the equivalent of more than 80,000 people displaced each day,” said Alexandra Bilak, Director of IDMC. “The scale of this displacement is dishearteningly familiar. This report shows why we need a new approach to address the huge costs of internal displacement, not only to individuals, but also to the economy, stability and security of affected countries.” Key findings

Akastor ASA: Equinor awards AKOFS Offshore Letter of Intent

16 May 2018 - AKOFS Offshore, a company owned by Akastor ASA, has entered into a Letter of Intent with Equinor for provision of year round light well intervention services (LWI) on the Norwegian continental shelf. Pursuant to the Letter of Intent, the contract period is for five years, with an option period of three years. Contract award is subject to partner approval and final agreement on terms and conditions. The contract value for the initial five-year period is approximately USD 370 million. The work is scheduled to commence first half of 2020 and will be performed from the AKOFS

Ahlsell publishes a MTN programme with an aggregate nominal amount of MSEK 5,000

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE OF THIS PRESS RELEASE WOULD BE UNLAWFUL. The Board of Directors of Ahlsell AB has resolved to establish a medium term note programme (the "MTN Programme") with a framework amount of MSEK 5,000. For this purpose, Ahlsell has prepared a base prospectus, which today has been approved by and registered with the Swedish Financial Supervisory Authority (Finansinspektionen).“The main

Invitation to Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018

Meet the future of antibody-based immuno-oncology drugsLund, Sweden, May 16, 2018 - Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, invites analysts, investors and media to its capital markets day in Stockholm on Tuesday May 29, 2018.  The program will start at 2:00 pm CEST, with registration from 1:00 pm CEST and will end with networking at 5:00 pm CEST. The event will take place at GT30, room Turbinen, Grev Turegatan 30 in Stockholm. The event will include presentations by Professor Carl

Viking Line introduces a delicious new children’s summer buffet

During summer 2018, Viking Line’s young passengers will enjoy an even healthier and better spread at our all new children’s buffet. The new menu is designed by juniors for juniors: the chef behind the menu is Victor Magdeburg of Sweden’s Junior Culinary Team.Eating well is an essential part of the ship experience for passengers of all ages. For this reason, Viking Line set out to develop tasty, high-quality alternatives to traditional children’s dishes without compromising on flavour or nutrition.  Children of the members of the Swedish Culinary Team tested the proposed new dishes.

EU funding for CombiGene’s epilepsy project is directly relevant for Panion’s epilepsy project

Tuesday the 15.th of May, late afternoon, CombiGene’s CEO Jan Nilsson released the news that the EU framework programme for research and development, Horizon 2020, will invest 3.6 million euros in CombiGene’s ongoing development and commercialization of their gene therapy project focusing on difficult-to-treat epilepsy in humans. During 2017, CombiGene presented three successful preclinical studies in the development of a gene-therapeutic treatment of difficult-to-treat epilepsy in humans. In January 2018, CombiGene chose British CGT Catapult as a partner for development of a complete and

ChemoTech’s distributor ABEX receives ‘Special Access’

Distributor Abex Medical System Sdn. Bhd. (ABEX), has together with “Pusat Perubatan Universiti Malaya” (PPUM), received 'Special Access', a special license to import IQWave™.When ChemoTech signed the distributor agreement with ABEX in the beginning of the year, we were aware of the requirement of local registration prior to commercialization. A presentation of IQWave™ held at the oncology department at PPUM resulted in the hospital requesting "Special Access" at the authorities to import non-registered medical equipment or drugs in a country. The purpose of this license is that PPUM will

Ascelia Pharma has raised SEK 60 million to finalize phase III preparations for Mangoral®

Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products. The equity injection of SEK 60 million will be used to advance the development of Ascelia Pharma’s drug candidates – Mangoral® and Oncoral.“I am highly satisfied with the support from both current and new shareholders and their confidence in Ascelia Pharma and our promising drug candidates. The funding will enable us to finalize preparations for the Mangoral® Phase III clinical study as well as complete the ongoing Oncoral Phase I study”, says Magnus Corfitzen, Chief

There are no items matching the current filter
There are no more items matching the current filter
Back to top